The Company reported net income for the three months ended August 31, 2025 of $749,000, or $0.09 per basic share and diluted share, compared to net income of $1.05 million, or $0.13 per basic and ...
In mid-May, Duke terminated its controversial Patent and Technology License Agreement with the umbilical cord blood and cord tissue stem cell bank Cryo-Cell International, Inc., after almost five ...
The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence ...
FibroBiologics, Inc. has announced the completion of its proprietary master cell bank, which will support its upcoming clinical trials. Developed in partnership with Charles River Laboratories and ...
The Company reported net income of $356,000, or $0.04 per basic and diluted common shares for the three months ended May 31, 2025, compared to net income of $656,000, or $0.08 per basic and diluted ...
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, ...
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback